Anthony J. Hickey

Back to the future: inhaled drug products.

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.

Controlled delivery of inhaled therapeutic agents.

Scale of health: indices of safety and efficacy in the evolving environment of large biological datasets.

The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.

Targeting inhaled therapy beyond the lungs.

In vitro dry powder inhaler formulation performance considerations.

Inhaled drug treatment for tuberculosis: Past progress and future prospects.

Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC).

A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals.

Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Nanomaterial Drug Products: Manufacturing and Analytical Perspectives.

Systems biology for organotypic cell cultures.

Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach.

Density and Shape Factor Terms in Stokes' Equation for Aerodynamic Behavior of Aerosols.

Reproducibility, sharing and progress in nanomaterial databases.

Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.

Effects of Formulation Variables on Lung Dosimetry of Albuterol Sulfate Suspension and Beclomethasone Dipropionate Solution Metered Dose Inhalers.

Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.

Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.

Exploiting machine learning for end-to-end drug discovery and development.

A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.

Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies.

Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Emerging trends in inhaled drug delivery.

Synergistic drug combinations and machine learning for drug repurposing in chordoma.

Designing inhalable metal organic frameworks for pulmonary tuberculosis treatment and theragnostics via spray drying.

A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans.

User-life of ICS/LABA inhaler devices should be considered when prescribed as relievers.

Microfluidic and Organ-on-a-Chip Approaches to Investigate Cellular and Microenvironmental Contributions to Cardiovascular Function and Pathology.

Inhaled antibodies: Quality and performance considerations.

A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease.

Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.

In vitro-in vivo correlation of pharmaceutical aerosols.

COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea.

Nanoformulated Remdesivir with Extremely Low Content of Poly(2-oxazoline)-Based Stabilizer for Aerosol Treatment of COVID-19.

Efficacy of inhaled CPZEN-45 in treating tuberculosis in the guinea pig.

Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment.

Multiple approaches to repurposing drugs for neuroblastoma.

Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.

Spray dried tigecycline dry powder aerosols for the treatment of Nontuberculous mycobacterial pulmonary infections.

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration.

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics.

Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.